Author of

• 15209

  +

  P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Advanced Diseases - NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15248

    +

    P3.01-039 - Patient Characteristics and Treatment Outcome of Advanced Non-Squamous NSCLC with over 6-Month Disease Control from Icotinib (ID 2806)

    09:30 - 09:30  |  Author(s): S. Zhou
    • Abstract
    • Slides

    Background:
    Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has an established role in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC). Icotinib is an EGFR-TKI with non-inferior efficacy but milder toxicities compared with gefitinib. Disease control for over 6 months suggests that the case is not primary resistant to the drug. The present study investigated the patient characteristics and treatment outcome of advanced non-squamous NSCLC with at least 6-month disease control from icotinib.
    
    Methods:
    Non-squamous NSCLC patients with disease control after 6-month icotinib treatment were enrolled and retrospectively analyzed. Clinical characteristics were collected from the medical records. Efficacy and outcome data were analyzed.
    
    Results:
    A total of 87 patients were enrolled onto this study in which 56 were female, 18 with brain metastasis, and 32 patients harbored known EGFR mutation. For the overall population, 42(48.3%) patients achieved partial response. Response rate were 65.6%（21/32）and 38.2%（21/55）in patients with EGFR mutation and those with unknown mutation status, respectively(P=0.014). Patients with brain metastasis appeared to have lower response rate (26.7% vs 56.9%, p=0.033).The median progression-free survival (PFS) after 6 months’ icotinib treatment was 9.7 months (95% CI 4.1-15.4 months) for the overall population, and 5.0 months (95% CI 0.6-3.9 months) and 12.9 months (95% CI 3.4-6.2 months) for those with and without brain metastasis, respectively. Median progression-free survival in patients with PR or SD showed no statistically significant difference (15.5 months vs 9.3 months, P=0.477).
    
    Conclusion:
    The present study provided evidence from a relatively large single institutional study of icotinib in clinical practice. Patients with disease control for over 6 months showed similar clinical features to those with EGFR mutation. Those patients will have prolonged clinical benefits with continuous icotinib therapy after 6 months, regardless of PR or SD. Brain metastasis is a potential unfavorable predictive factor for PFS for those patients
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.